Darpones and water-soluble aminobutoxylated darpone derivatives are distinguished by matrix COMPARE analysis

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 7, 2007, Pages 1850-1854

  Prühs, Christian ^a   Kunick, Conrad ^a  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

Author keywords

Antiproliferative activity; Compare analysis; Darpones; Solubility

Indexed keywords

ANTINEOPLASTIC AGENT; DARPONE DERIVATIVE; MORPHOLINE DERIVATIVE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HETEROCYCLIC COMPOUNDS, 3-RING; LACTONES; MODELS, CHEMICAL; MOLECULAR CONFORMATION; SOFTWARE; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33847610134     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.01.043     Document Type: Article

References (16)

1. Link A., and Kunick C. J. Med. Chem. 41 (1998) 1299
2. Link A., Zaharevitz D.W., and Kunick C. Pharmazie 54 (1999) 163
3. Monks A., Scudiero D.A., Johnson G.S., Paull K.D., and Sausville E.A. Anti-Cancer Drug Des. 12 (1997) 533
4. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., and Boyd M. J. Natl. Cancer Inst. 83 (1991) 757
5. Boyd M.R., and Paull K.D. Drug Dev. Res. 34 (1995) 91
6. Hollingshead M., Alley M., Camalier R., Abbott B., Mayo J., Malspeis L., and Grever M. Life Sci. 57 (1995) 131
7. Schultz C., Link A., and Kunick C. Arch. Pharm. Pharm. Med. Chem. 334 (2001) 163
8. Wosikowski K., Schuurhuis D., Johnson K., Paull K.D., Myers T.G., Weinstein J.N., and Bates S.E. J. Natl. Cancer Inst. 89 (1997) 1505
9. Rabow A., Shoemaker R., Sausville E., and Covell D. J. Med. Chem. 45 (2002) 818
10. Keskin O., Bahar I., Jernigan R., Beutler J., Shoemaker R., Sausville E., and Covell D. Anti-cancer Drug Des. 15 (2000) 79
11. Weinstein J.N., Myers T.G., O'Connor P.M., Friend S.H., Fornace Jr. A.J., Kohn K.W., Fojo T., Bates S.E., Rubinstein L.V., Anderson N.L., Buolamwini J.K., van Osdol W.W., Monks A.P., Scudiero D.A., Sausville E.A., Zaharevitz D.W., Bunow B., Viswanadhan V.N., Johnson G.S., Wittes R.E., and Paull K.D. Science 275 (1997) 343
12. Kunick C. Curr. Med. Chem. Anti-Cancer Agents 4 (2004) 421
13. Paull K.D., Shoemaker R.H., Hodes L., Monks A., Scudiero D.A., Rubinstein L., Plowman J., and Boyd M.R. J. Natl. Cancer Inst. 81 (1989) 1088
14. McOmie J.F.W., Watts M.L., and West D.E. Tetrahedron 24 (1968) 2289
15. Bach S., Knockaert M., Reinhardt J., Lozach O., Schmitt S., Baratte B., Koken M., Coburn S.P., Tang L., Jiang T., Liang D.-C., Galons H., Dierick J.-F., Pinna L.A., Meggio F., Totzke F., Schaechtele C., Lerman A.S., Carnero A., Wan Y., Gray N., and Meijer L. J. Biol. Chem. 280 (2005) 31208
16. Knockaert M., Wieking K., Schmitt S., Leost M., Grant K.M., Mottram J.C., Kunick C., and Meijer L. J. Biol. Chem. 277 (2002) 25493